Funded Projects › HORIZON
IVM-KIDS · Accelerating a paediatric formulation of ivermectin for the control of Neglected Tropical Diseases
Ivermectin is a critical drug for the control and elimination of multiple neglected tropical diseases. Currently, children weighing under 15kg do not receive treatment with ivermectin due to an absence of safety data and the lack of a suitable paediatric formulation. Consequently, these children are left untreated. This results in considerable morbidity at the individual level and a reservoir of infection at the population level. These issues create a critical barrier to achieving the goals of the 2030 NTD roadmap. In 2023, the World Health Organization (WHO) conducted a Paediatric Drug Optimisation (PADO) review to identify critical needs for therapeutics in children affected by NTDs. Recognising the central role of ivermectin in the control of NTDs, along with the opportunity to accelerate progress by expanding treatment to paediatric populations, this report highlighted a paediatric-friendly ivermectin formulation as as a critical priority for NTD programmes worldwide. A novel orodispersible formulation of ivermectin provides the opportunity to address this critical gap. Our consortium brings together leading academic and drug development partners across Europe and sub-Saharan Africa to address this global priority need, with crucial experience in novel therapeutics and navigating the European and African regulatory landscapes.Our consortium will deliver studies to demonstrate the safety, pharmacokinetics and efficacy of the novel, orodispersible formulation of ivermectin suitable for use in young children. This will include conducting a large safety study across West, Central, East and Southern Africa to demonstrate the efficacy of this agent for the treatment of soil transmitted helminthiasis. We will work closely with European and African regulators to ensure that our project delivers both the scientific and regulatory data required to bring this agent to market and transform access to effective NTD treatment for for millions of children worldwide.
Consortium · 9 organisations
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER
UK · €1,671,785
LABORATORIOS LICONSA SA
ES · €556,338
INSTITUT NATIONAL DE RECHERCHE BIOMEDICALE DU ZAIRE
CD · €719,500
KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY KUMASI
GH · €1,092,450
SCHWEIZERISCHES TROPEN UND PUBLIC HEALTH INSTITUT
CH
AFRICAN PHARMACEUTICAL TECHNOLOGY FOUNDATION
RW · €100,000
DRUGS FOR NEGLECTED DISEASES INITIATIVE FONDATION
CH
FUNDACION MUNDO SANO ESPANA
ES · €587,500
KENYA MEDICAL RESEARCH INSTITUTE
KE · €771,178
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.